Magnesium is a cofactor for more than 300 enzymatic reactions in the human body, many of which sit squarely at the intersection of energy metabolism and insulin signaling. It is required for the phosphorylation of the insulin receptor and for the translocation of glucose transporter type 4 (GLUT4) to the cell membrane, the rate-limiting step in glucose uptake by skeletal muscle and adipose tissue. Population studies have repeatedly linked low magnesium intake with a heightened risk of metabolic syndrome and incident diabetes, yet randomized trials using conventional supplements have yielded mixed results. One hypothesis for this inconsistency is that the bioavailability and physiological impact of magnesium are tightly coupled to the food matrix in which it is embedded. Whole-food concentrates retain phytates, polyphenols, and organic acids that may chelate the mineral, protect it from gastrointestinal precipitation, and facilitate absorption via paracellular and transcellular pathways that isolated salts cannot engage as effectively.

Basiri’s study will enroll adults with elevated fasting blood glucose or impaired glucose tolerance, a cohort that captures the latent pathophysiology before a formal diabetes diagnosis. The intervention is E‑Z Mg, a product manufactured by Standard Process that starts with organically grown vegetables, fruits, and grains, which are then dehydrated and concentrated at low temperatures to preserve heat-sensitive bioactive compounds. The final powder is encapsulated without binders or synthetic excipients. The trial will track glycated hemoglobin, fasting insulin, and homeostatic model assessment of insulin resistance as primary glycemic endpoints, while secondary endpoints include actigraphy-measured sleep efficiency, the Profile of Mood States questionnaire, the Multidimensional Fatigue Inventory, ambulatory blood pressure, and dual-energy X-ray absorptiometry scans for visceral adipose tissue and lean mass distribution.

What makes this investigation particularly timely is the emerging understanding of sleep and mood as modulators of insulin sensitivity via the hypothalamic-pituitary-adrenal axis and the sympathetic nervous system. Magnesium acts as a physiological antagonist of the N-methyl-D-aspartate (NMDA) receptor and promotes gamma-aminobutyric acid (GABA) receptor activity, effects that dampen excitatory neurotransmission and facilitate sleep onset. Simultaneously, magnesium deficiency upregulates cortisol and catecholamine release, which directly counteracts insulin action and drives lipolysis, feeding a vicious cycle of hyperglycemia, fragmented sleep, and fatigue. By examining these pathways in parallel, Basiri hopes to disentangle whether magnesium’s metabolic benefits operate independently or are mediated through improvements in sleep architecture and affective state. If the whole-food supplement demonstrates superiority, it could shift clinical guidelines toward favoring food-derived mineral complexes over synthetic isolates.

The project has attracted a $237,345 grant from Standard Process, the Wisconsin-based nutraceutical company that developed E‑Z Mg. Funding is scheduled to run from May 2026 through May 2027, a relatively compact timeline that suggests a focused, high-intensity trial design. While industry-sponsored research often raises questions of objectivity, the study will be conducted under the institutional oversight of George Mason University, with rigorous blinding and independent data management protocols intended to safeguard scientific integrity. Basiri has expressed a clear scientific mission: to produce actionable data that can inform dietary recommendations for the estimated 96 million American adults who currently have prediabetes.

George Mason’s emergence as a hub for translational health research provides a robust ecosystem for this work. As Virginia’s largest public research university, located in the Washington, D.C. metropolitan area, it draws a diverse participant pool that reflects the demographic mosaic in which diabetes disparities are most stark. The university’s College of Public Health has been scaling up its portfolio of nutrition and metabolic disease studies, leveraging partnerships with regional hospital systems and community health networks to accelerate recruitment and translate findings into community-based prevention programs. This trial could add a significant piece to the puzzle of how micronutrient supplementation, when designed to align with evolutionary dietary patterns, might offer a low-cost, scalable tool against the diabetes epidemic. If the results confirm that a whole-food magnesium complex can simultaneously tighten glycemic control, lower blood pressure, and restore restorative sleep, it could redefine the conversation around supplementation from mere nutrient replacement to functional food pharmacology.

Subject of Research: Effects of a whole-food-derived magnesium supplement on sleep, mood, fatigue, blood pressure, body composition, and glycemic control in adults with elevated blood glucose
Article Title: Can a Whole-Food Magnesium Supplement Rewire Metabolism in Prediabetes?
News Publication Date: May 2025
Web References: Mason Now campaign, George Mason University
References: None provided
Image Credits: None provided
Keywords: Magnesium supplementation, prediabetes, glycemic control, whole-food concentrate, insulin resistance, sleep quality, blood pressure, body composition, E‑Z Mg, Standard Process